Top Markets
#1 Akedo Akedo +57.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.04%
#4 Velvet Velvet +42.35%
#5 Black Phoenix Black Phoenix +34.54%
#6 Ο„emplar Ο„emplar +23.53%
#7 Cross Cross +20.01%
#8 Ribbita by Virtuals Ribbita by Virtuals +16.20%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.39%
#10 Perle Perle +15.05%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Rank in Stocks #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Share Price
$0.02468497
Market Cap
$1.01M
Change (1 day)
-12.50%
Change (1 year)
-87.34%
Country
AU
Trade Chimeric Therapeutics Limited (CHM)

Category

Healthcare
Operating Margin for Chimeric Therapeutics Limited (CHM)
Operating Margin as of 2026 TTM: 0.00%
According to Chimeric Therapeutics Limited latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Chimeric Therapeutics Limited from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.